Oscar said he was surprised the treatment could pack such a powerful punch in such a small dose.
“It’s very sci-fi, but if it means it gets rid of the cancer permanently and my own cells can do it it’s just fantastic.”
Oscar had a second infusion of 300 million cells yesterday, marking the end of his CAR-T treatment.
As this is a “living drug”, the cancer-killing T-cells stay in the body for a long time and will continue to grow and work inside the patient after the final infusion.
The CAR-T therapy is manufactured by Autolus, a spin-out company from University College London.
During clinical trials, the patient’s cells had to be sent to laboratories in the US.
The list price of the treatment is £372,000 per infusion, external, but the NHS has a confidential discount.
It will be available to patients over the age of 26 whose B-cell ALL has not responded to treatment or has returned at several centres in England, including Cambridge, Newcastle, Sheffield, Plymouth and London.
Patients from Wales and Northern Ireland will need to travel to England for treatment. It has not yet been approved in Scotland.
NHS England estimates that around 50 patients a year may benefit, but Tholouli told the BBC she believed it could be more, and predicted it would eventually be used as a first-line treatment instead of stem cell transplantation.
Prof Peter Johnson, NHS National Clinical Director for Cancer, said it was a “landmark moment” for people with aggressive blood cancer.
He added it was “remarkable” the treatment now delivered at NHS centres had been developed from scientific research within the UK.
“It will help more people like Oscar live longer and healthier lives.”